Pharmaceutical News

RSS

Age Intervention Eyelash products seized by U.S. Marshals

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized today 12,682 applicator tubes of Age Intervention Eyelash, a product that may, in some users, lead to decreased vision.

19 Nov 2007

Eyelash growth product can damage vision

American consumers are being warned by the Food and Drug Administration (FDA) about the dangers of a product which promises to increase eyelash growth.

19 Nov 2007

New proposed monographs for dietary supplements

The U.S. Pharmacopeia (USP) is pleased to announce 11 new proposed monographs for dietary supplements for public notice and comment.

16 Nov 2007

FDA to improve advisory committee processes

The Food and Drug Administration is announcing several steps to strengthen its advisory committee processes in ways consistent with recommendations of the Institute of Medicine.

16 Nov 2007

Rising drug expenditures for ADHD

The NHS is likely to face a 10-fold increase in the cost of drugs prescribed to children and adolescents with attention-deficit/hyperactivity disorder (ADHD) in the decade to 2012.

16 Nov 2007

Drug to treat children with bipolar disorder gets priority review

An anti-psychotic drug already approved in the U.S. to treat adults and adolescents with schizophrenia may soon be available for youngsters age 10 to 17 years of age suffering from bipolar disorder.

15 Nov 2007

Top selling diabetes drug to carry back box warning

The government watchdog body in the U.S., The Food and Drug Administration (FDA), has placed a "black box" warning on the popular drug Avandia.

15 Nov 2007

GlaxoSmithKline implements changes to the US product label for Avandia

GlaxoSmithKline announced today that it is implementing changes to the US product label for Avandia(R) (rosiglitazone maleate), based on an extensive and thorough review by the FDA of myocardial ischemia data on Avandia, the most widely studied oral anti-diabetic medicine available.

15 Nov 2007

Petition aims to stem the flood of dangerous drugs reaching Americans

In a petition filed with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.

15 Nov 2007

FDA adds warning for heart attacks to type 2 diabetes drug Avandia

The U.S. Food and Drug Administration announced today that the manufacturer of Avandia (rosiglitazone), a drug used to treat type 2 diabetes, has agreed to add new information to the existing boxed warning in the drug's labeling about potential increased risk for heart attacks.

14 Nov 2007

Sanofi Pasteur and Acambis to bring West Nile vaccine to market

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has signed an exclusive global collaboration agreement with Acambis plc, for the development and marketing of a West Nile vaccine to help fight against this serious, life-altering and potentially fatal disease.

14 Nov 2007

Pfizer and Nektar resolve outstanding Exubera contractual issues

Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.

14 Nov 2007

Nanoviricide drug candidate effectiveness confirmed against rabies and influenzas

NanoViricides, Inc. has said that in a confirmatory study, their nanoviricide drug candidates exhibited a consistent 20% to 30% survival in the test animals.

13 Nov 2007

Lexicon files investigational NDA for LX2931 in rheumatoid arthritis

Lexicon Pharmaceuticals, Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX2931, an oral drug candidate for rheumatoid arthritis and other autoimmune conditions.

13 Nov 2007

FDA strengthens warnings for erythropoiesis-stimulating agents

The U.S. Food and Drug Administration has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs), which treat certain types of anemia.

13 Nov 2007

FDA approves new nonprescription allergy drug Zyrtec-D

The Food and Drug Administration (FDA) has approved Zyrtec-D (cetirizine HCl 5 mg and pseudoephedrine HCl 120 mg), an allergy drug, for nonprescription use in adults and children 12 years of age and older. This drug combines an antihistamine with a nasal decongestant.

13 Nov 2007

Seattle Post-Intelligencer examines reactions of people who participated in Merck's canceled HIV vaccine

The Seattle Post-Intelligencer on Friday examined the reaction of volunteers in the Seattle arm of Merck's recently halted HIV vaccine trial. According to the Post-Intelligencer, participants who were interviewed on the condition of anonymity have voiced "decidedly mixed feelings" about participating in the trial because of safety concerns (Paulson, Seattle Post-Intelligencer, 11/9).

12 Nov 2007

Potential block buster on the horizon - new vaccine to control high blood pressure

A vaccine that would help people control their blood pressure is showing promise in early trials.

7 Nov 2007

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Bayer Pharmaceuticals agrees to a marketing suspension of Trasylol

The U.S. Food and Drug Administration (FDA) has announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.

5 Nov 2007